BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19856030)

  • 1. Lymph node metastases in diffuse malignant peritoneal mesothelioma.
    Baratti D; Kusamura S; Cabras AD; Laterza B; Balestra MR; Deraco M
    Ann Surg Oncol; 2010 Jan; 17(1):45-53. PubMed ID: 19856030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
    Yan TD; Yoo D; Sugarbaker PH
    Eur J Surg Oncol; 2006 Nov; 32(9):948-53. PubMed ID: 16806796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
    Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
    Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
    Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
    J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study.
    Baratti D; Kusamura S; Cabras AD; Deraco M
    Ann Surg Oncol; 2012 May; 19(5):1416-24. PubMed ID: 22302266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
    Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
    Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
    Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
    Yan TD; Brun EA; Cerruto CA; Haveric N; Chang D; Sugarbaker PH
    Ann Surg Oncol; 2007 Jan; 14(1):41-9. PubMed ID: 17039392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience.
    Chua TC; Yan TD; Morris DL
    J Surg Oncol; 2009 Feb; 99(2):109-13. PubMed ID: 19016259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
    Deraco M; Casali P; Inglese MG; Baratti D; Pennacchioli E; Bertulli R; Kusamura S
    J Surg Oncol; 2003 Jul; 83(3):147-53. PubMed ID: 12827682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
    Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR
    J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
    González-Moreno S; Brun E; Sugarbaker PH
    Ann Surg Oncol; 2005 Jan; 12(1):72-80. PubMed ID: 15827781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.